TK216

Research use only, not for human use.

TK216 is a potent inhibitor of E26 transformation-specific (ETS) with anticancer activity.In DLBCL cell lines, TK216 (500 nM; for 24-72 hours) induces apoptosis.

TK216 is a potent inhibitor of E26 transformation-specific (ETS) with anticancer activity.In DLBCL cell lines, TK216 (500 nM; for 24-72 hours) induces apoptosis. TK216 (0.03, 0.06, 0.125, 0.25, 0.5 μM) results in a dose-dependent inhibition of proliferation in Ewing Sarcoma A4573 cell line. In DLBCL cell lines, TK216 (0.1, 0.3, 1 μM) induces apoptosis, with the amount of cleaved-Caspase 3 normalized to b-actin and presented as fold over control. TK216 has IC50s of 0.363 μM and 0.152 μM for the HL-60 AML cell line and TMD-8 DLBCL cell line. TK216 inhibits EWS-FLI1 (Ewing sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein) protein interactions, leading to a decrease in transcription and proliferation.In the TMD-8 xenograft model, TK216 (po; 100 mg/kg; twice daily for 13 days) results in tumor growth inhibition.

Apoptosis Analysis Cell Line:DLBCL cell lines Concentration:500 nM Incubation Time:For 24, 48 or 72 hours Result:Induced apoptosis in DLBCL cell lines.

Animal Model:NOD-Scid mice subcutaneously inoculated with TMD8 cells Dosage:100 mg/kg Administration:PO; twice daily for 13 days Result:Resulted in tumor growth inhibition.

——

Others

Other Targets

ETS

Cancer

Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia

1903783-48-1

376.23

C19H15Cl2NO3

>98% (HPLC)

DMSO:249 mg/mL(661.83 mM)

OC1(CC(=O)c2ccc(cc2)C2CC2)C(=O)Nc2c1c(Cl)ccc2Cl

——

(-20℃)

With Ice Pack

≥ 2 years